Company news

Ligand Pharmaceuticals Incorporated news in 2023

Ligand Pharmaceuticals Incorporated's news releases, calls and decks from 2023, newest first.

View company

Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance

December 11, 2023

Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City

December 5, 2023

Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications

November 30, 2023

Ligand Reports Third Quarter 2023 Financial Results

November 7, 2023

Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million

October 31, 2023

Ligand To Report Third Quarter 2023 Financial Results On November 8

October 24, 2023

Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026

October 17, 2023

Ligand Acquires Assets of Novan, Inc. for $12.2 Million

September 26, 2023

Ligand Appoints Martine Zimmermann to its Board of Directors

September 25, 2023

Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

September 21, 2023

Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio

September 17, 2023

Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

August 31, 2023

Ligand Reports Second Quarter 2023 Financial Results

August 7, 2023

Ligand’s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials

July 26, 2023

Ligand To Report Second Quarter 2023 Financial Results On August 8

July 24, 2023

Ligand Offers $15 Million to Acquire Assets of Novan, Inc.

July 16, 2023

Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

May 15, 2023

Ligand Reports First Quarter 2023 Financial Results

May 3, 2023

Ligand to Report First Quarter 2023 Financial Results on May 4, 2023

April 23, 2023

Ligand Reports Fourth Quarter and Full Year 2022 Financial Results

February 21, 2023

Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

February 16, 2023

Ligand to Report Fourth Quarter Financial Results on February 22

February 5, 2023

Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum

January 5, 2023

Calls in 2023

Decks in 2023